Due to its strong inclusiveness and attractiveness, the Science and Technology Innovation Board has become the main listing place
for innovative pharmaceutical companies.
Here, pharmaceutical companies in the R&D stage have the opportunity to obtain capital attention, and non-profit pharmaceutical companies with hard technology attributes can also receive favorable support to accelerate the research and development and innovation
of key core technology products.
Up to now, the listed companies on the Science and Technology Innovation Board have basically disclosed the 2022 semi-annual report, and from the report, we can get a glimpse of the research and development of pharmaceutical companies listed on the
Science and Technology Innovation Board.
Salary increase! In the first half of the year, the average salary of R&D personnel of a large number of pharmaceutical companies increased (Source: Pharmaceutical Network)
From the perspective of R&D investment scale, in the first half of 2022, the R&D investment of pharmaceutical companies listed on the Science and Technology Innovation Board increased significantly, of which more than 10 pharmaceutical companies listed only on the fifth set of standards on the Science and Technology Innovation Board reached 4.
258 billion yuan, an increase of more than 10%
At the same time, there is also a situation that in the first half of the year, the average salary of R&D personnel of a large number of pharmaceutical companies has increased, such as BeiGene, Yahong Pharmaceutical, Haoyuan Pharmaceutical, Zejing Pharmaceutical, Rongchang Biologics, BIO and other companies at least more than 20 companies have a certain growth, the increase range of 1
% to 87%.
According to the combing point of view, the average salary of R&D personnel in BeiGene in the first half of the year was higher, reaching 501,000, an increase of 15% year-on-year, and the annual salary is expected to exceed one million
It was followed by Di zhe pharmaceutical and Yahong Pharmaceutical, with an average salary of 358,800 yuan and 276,300 yuan
From the perspective of the number of R & D personnel, BeiGene currently has 3029 R & D personnel, an increase of 552 people year-on-year, an increase of 22.
29%, followed by Medici, the number of R & D personnel is 2454 people
In addition, junshi biological, Rongchang biological research and development personnel are also more than 1,000 people
Compared with the first half of 2021, the average salary increase of R&D personnel in many pharmaceutical companies in the first half of this year exceeded 50%.
Among them, the average salary of R&D personnel in Shanghai Yizhong in the first half of the year increased by 87% year-on-year, reaching 110,100 yuan, and the estimated annual salary was about 200,000 yuan, but the company's investment in research and development expenses was relatively small compared with other companies, only 0.
03 billion yuan; the per capita salary of Yaokang Bio in the first half of the year increased by 77% year-on-year, the average salary was 147,700 yuan, and the estimated annual salary was close to 300,000 yuan; in addition, the per capita salary of Kexing Pharmaceutical increased by 52%, and the growth rate of Rongchang Bio was also close to 50%, which was 46
However, there are salary increases in pharmaceutical companies, and there are also wage
cuts in enterprises.
For example, the average salary of R&D personnel in the first half of 2022 was 234,100 yuan, but it decreased by 9%
In addition, the average salary of Chengdu pilot R&D personnel also decreased, down 2% year-on-year to 143,700 yuan
The industry believes that biological innovative drug enterprises have the characteristics of high R & D investment, long return period, large risk, etc.
, and high-intensity R&D investment is the key
to maintaining the core competitiveness of enterprises.
In recent years, with the continuous increase in the importance of R&D investment by pharmaceutical companies, R&D investment has gradually transformed into a driving force to support the sustainable development of innovative pharmaceutical companies, which has brought substantial growth in performance to some companies and increased
the salaries of R&D personnel.
For example, in the first half of the year, the average salary of R&D personnel increased by 46% year-on-year, Rongchang Bio, which is a fifth set of standard listed companies with 2 listed drugs
In the first half of this year, the company achieved operating income of 350 million yuan, an increase of more than 1029.
over the same period of the previous year.
It should be noted that for some pharmaceutical companies, especially unprofitable pharmaceutical companies, on the one hand, it is a continuous high investment in research and development, on the other hand, it may also face the challenge of intensifying competition in important products, resulting in insufficient "blood replenishment", which makes the salaries of R& D personnel also affected to a certain extent
For example, Junshi Bio is facing the challenge
of burning money and "inner volume".
In the first half of this year, junshi biological research and development expenses accounted for 112.
28% of revenue, which can be described as a large-scale "burning money", in addition, its core product, the PD-1 market where the core product of triprimumab is located, is also intensifying, these two factors have brought the company's performance continued losses, with a loss of 900 million yuan
in the first half of this year.
In order to "replenish blood", Junshi Bio recently updated the pre-increase plan, and the proposed increase in funds should not exceed 3.
969 billion yuan for the research and development project of innovative drugs and the project of Shanghai Junshi Biotechnology Headquarters and R&D Base
In the industry's view, the development of innovative drugs can not be separated from R & D investment, most of the listed pharmaceutical companies on the science and technology innovation board to increase research and development efforts, the introduction of more R & D talents, the salary increase for R & D personnel are conducive to the development of enterprises and innovative drug industry initiatives, I believe that the future industry will move forward
in the direction of high quality.